Visa Inc. V is set to report third-quarter fiscal 2021 results on Jul 27, after the market closes. Both revenues and earnings are expected to be higher for the June quarter.Earnings & Revenue ExpectationsThe Zacks Consensus Estimate for Visa’s third-quarter fiscal 2021 earnings of $1.32 per share implies an increase of 24.53% from the prior-year period’s reported number. Likewise, the consensus estimate for sales of $5.82 billion suggests a 20.32% rise from the year-ago quarter’s reported figure.FactorsFactors Likely to Impact Q3 ResultsConsumers as well as merchants adapted to digital payments bigtime in the face of the ongoing pandemic, given the ease, convenience and security the same offers. These trends bode well for this payment processor.The company draws revenues as a set percentage of the total transaction value everytime a customer’s debit/credit card is used for making payments. Thus, higher spending on its cards means more revenues in the form of transaction processing fees.After witnessing low spending last year due to COVID-19, Visa’s operational metrics, such as payment volumes (the primary lever of service revenues), processed transactions (the primary driver of data processing revenues) and cross-border volumes are likely to have bettered in the to-be-reported quarter.Pent-up demand, bigger savings and an upbeat consumer sentiment prompted people to spend more in recent months. Retail sales have been trending up higher for sometime now. These are expected to have boosted payment volumes and processed transactions for the company.One headwind for Visa was low travel spend as people avoided taking trips. This is now recovering as Americans are resorting domestic travel.International travel is yet to pick up the pace. It is a vital area as it contributes to cross-border revenues and emerges as a major component of the company’s top line, carrying higher margins.A rebound in international travel was very much expected but with the Delta variant of the COVID-19 surfacing everywhere, the space can take more time to regain its lost ground.Visa performed well in the first half of fiscal 2021 with growth registered in payments volume as well as in the number of processed transactions, reflecting better operating efficiency.In the fiscal second quarter, management expected net revenue growth for the fiscal third quarter to be in the high teens if stable-to-improving economic trends continue.Operating expenses are likely to have escalated amid stepped up investments for marketing and key initiatives to capture growth opportunities.Earnings Surprise HistoryThe company boasts an attractive earnings surprise record with its bottom line having surpassed estimates in each of the last four quarters, the average being 7%. This is depicted in the chart below:Visa Inc. Price and EPS Surprise Visa Inc. price-eps-surprise | Visa Inc. QuoteEarnings WhispersOur proven model predicts a beat for Visa this earnings season. The combination of the two key ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or better — increases the odds of a positive surprise, which is the case here.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Earnings ESP: Visa has an Earnings ESP of +2.55%.Zacks Rank: Visa currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Other Stocks That Warrant a LookSome other stocks worth considering with the apt combination of elements to surpass estimates this reporting cycle are as follows:Discover Financial Services DFS has an Earnings ESP of +13.41% and is presently Zacks #3 Ranked.Global Payments Inc. GPN has an Earnings ESP of +1.78% and a Zacks Rank of 2, presently.Mastercard Inc. MA has an Earnings ESP of +0.98% and a Zacks Rank of 3 at present. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mastercard Incorporated (MA): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report Discover Financial Services (DFS): Free Stock Analysis Report Global Payments Inc. (GPN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research